Scilex Holding Company Deferred Federal Income Tax Expense (Benefit)
Scilex Holding Company (SCLX) reported Deferred Federal Income Tax Expense (Benefit) of $12.79 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-10.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredFederalIncomeTaxExpenseBenefit · last filed 2026-04-10
- Scilex Holding Company deferred federal income tax expense (benefit) for fiscal 2025 was $12.79M.
- Scilex Holding Company deferred federal income tax expense (benefit) for fiscal 2024 was -$16.28M.
- Scilex Holding Company deferred federal income tax expense (benefit) for fiscal 2023 was -$16.51M.
- Scilex Holding Company deferred federal income tax expense (benefit) for fiscal 2022 was -$10.40M.
| Period end | Deferred Federal Income Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | $12.79M 10-K · filed 2026-04-10 |
| 2024-12-31 | -$16.28M 10-K · filed 2026-04-10 |
| 2023-12-31 | -$16.51M 10-K · filed 2025-03-31 |
| 2022-12-31 | -$10.40M 10-K · filed 2024-03-12 |
| 2021-12-31 | -$12.98M 10-K · filed 2024-03-12 |
| 2020-12-31 | -$3.97M 10-K · filed 2023-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |